GLP-1 Price Tracker: May 2026 Update
Prices verified May 22, 2026 · Updated for 2026
May 2026 headline: Foundayo (orforglipron) launched at $149/mo, Novo Nordisk confirmed Wegovy list price cut to $675 starting Jan 2027, and the Medicare GLP-1 Bridge launches July 1 at $50/mo copay. Compounded pricing remains stable at $99–$299/mo. The gap between brand-name and compounded is narrowing faster than expected.
What changed this month
Foundayo launch reshapes oral pricing
Eli Lilly's Foundayo (orforglipron) launched in April 2026 at $149/month through LillyDirect—matching the Wegovy pill's introductory pricing. This is the first oral GLP-1 with no fasting restrictions, making it the most convenient daily option. At ~11% average weight loss, it trades some efficacy for ease of use.
Novo Nordisk's 2027 price cut confirmed
Novo Nordisk announced in February that Wegovy's list price will drop to $675/month starting January 1, 2027—roughly a 50% reduction from the current ~$1,349 list price. This won't affect most patients immediately (manufacturer programs and insurance already reduce the actual cost), but it signals a directional shift that could eventually lower compounded pricing pressure as well.
Medicare GLP-1 Bridge: 5 weeks out
The Medicare GLP-1 Bridge launches July 1, 2026, covering Wegovy, Zepbound, and Foundayo at a $50/month copay for eligible Medicare Part D beneficiaries. Eligibility: BMI ≥35, or BMI ≥27 with qualifying conditions. The Bridge runs through December 31, 2027 (extended from the original December 2026 end date). The BALANCE Model for Medicare Part D was cancelled on April 21, 2026.
Current verified pricing (May 2026)
| Medication/Provider | Type | Monthly cost | Change vs. April |
|---|---|---|---|
| GobyMeds semaglutide | Compounded | From $99 | No change |
| Oak Weight Loss | Compounded | $130 (flat rate) | No change |
| Yucca Health semaglutide | Compounded | From $146 (6-mo) | No change |
| Embody semaglutide | Compounded | $149 first / $299 | No change |
| Foundayo | Brand oral | $149 | NEW |
| Wegovy pill | Brand oral | $149–$299 | No change |
| Zepbound KwikPen | Brand injectable | $299–$699 | No change |
| Wegovy injection | Brand injectable | $349 (NovoCare) | No change |
| Medicare (July 2026) | Brand via Part D | $50 copay | UPCOMING |
Market trends
- Brand-compounded price convergence: With Foundayo at $149/mo and Wegovy pill at $149–$299/mo, the cheapest brand-name oral options now overlap with mid-tier compounded injectable pricing. This erodes compounding's primary advantage (price) while brand-name offers the regulatory certainty compounded can't.
- FDA enforcement continues: 30+ warning letters to GLP-1 telehealth companies in early 2026. Major compounding lab closures (ProRx, BPI Labs). The regulatory environment is tightening.
- Insurance expansion: Beyond Medicare, several major commercial insurers expanded GLP-1 coverage in 2026. Cigna launched a $200/mo Wegovy/Zepbound benefit. UnitedHealthcare expanded formulary access. Check your specific plan—coverage is changing faster than guides can track.
What to watch in June 2026
- Medicare GLP-1 Bridge launch (July 1) — will demand overwhelm supply?
- CagriSema FDA decision timeline update
- FDA compounding enforcement public comment period (closes June 29)
- Potential additional manufacturer cash-pay program adjustments ahead of Medicare launch
🏥 Compare Current Pricing
Compounded medications are not FDA-approved. Consult a licensed provider to determine if treatment is appropriate for you.
GobyMeds
LegitScript-verified. Semaglutide & tirzepatide bundles, free consult, free shipping.
Get StartedEmbody
Compounded semaglutide with metabolic report, 1:1 guidance, and personalized plan.
Start for $149Oak Weight Loss
Compounded semaglutide and tirzepatide at a single flat rate regardless of dose.
See PlansSesame Care
Access to FDA-approved brand-name GLP-1 medications through licensed providers.
Get StartedSources & References
- Provider pricing verified May 2026.
- CMS: Medicare GLP-1 Bridge design memo, March 2026.
- Novo Nordisk: Wegovy price reduction announcement, Feb 2026.
- Eli Lilly: Foundayo launch pricing, April 2026.
- KFF: "What Medicare's Temporary Program Covering GLP-1s Means for Beneficiaries." March 2026.